The use of high dose therapy and autologous bone marrow or stem cell transplant is an established treatment approach for fit patients with multiple myeloma. Preclinical data suggests that combining melphalan or other cytotoxic chemotherapy with the proteasome inhibitor bortezomib enhances the anti-myeloma effects of melphalan due to inhibition of DNA repair. In the current clinical trial report, we present data supporting this hypothesis with correlative studies demonstrating enhanced plasma cell apoptosis with sequence specificity. This correlative 
Introduction:
Multiple myeloma (MM) is a clonal plasma cell disorder characterized by lytic bone disease, renal dysfunction, abnormal hematopoietic function, and the presence of a monoclonal paraprotein in the blood and/or urine. Historical induction regimens rarely achieved major responses (VGPR or CR), and prior to the use of high dose therapy (HDT) and autologous transplant, few therapeutic options demonstrated significant improvements in overall survival for newly diagnosed myeloma patients 1, 2 . Led first by the Intergroupe Francophone du Myelome (IFM), several groups have now demonstrated improvements in overall response rate, progression free survival (PFS), and overall survival (OS) for patients randomized to receive HDT when compared with conventional dose chemotherapy 3 , rendering HDT a standard treatment approach for younger patients with newly diagnosed MM. In addition, the IFM has demonstrated that achievement of a very good partial remission (VGPR) is a surrogate for improvement in PFS and OS 4 , adding it as a new category in the revised international myeloma working group response criteria 5 . Despite these improvements, patients are rarely if ever cured of MM through the use of HDT. In order to improve the efficacy of the HDT maneuver itself, groups have explored the use of multiple cycles of HDT (tandem transplant) [6] [7] [8] , the use of combination chemotherapy conditioning regimens employing agents in addition to or replacing melphalan in HDT conditioning [9] [10] [11] [12] , and the addition of radiation therapy using targeted antibodies 13, 14 or external beam radiation 15 . Unfortunately, none of these approaches has been shown to be superior to the use of 200mg/m 2 of melphalan. Thus, if we are to improve on the efficacy of HDT, alternative combination approaches are needed.
Bortezomib is a boronated peptide inhibitor of the chymotryptic site of the proteasome, and has demonstrated efficacy in newly diagnosed, relapsed, and refractory multiple myeloma . Preclinical data using bortezomib demonstrates pleotrophic effects on plasma cell homeostasis, and suggests that the combination of an alkylating agent and bortezomib induces synergistic myeloma cell apoptosis 19, 20 . Mechanistically, this is thought to occur because bortezomib induces cleavage of DNA PKC's, enzymes used to facilitate repair of double stranded DNA breaks 21 . Clinical trials such as VISTA (MPV vs MP) 22 and MMY-3001
(bortezomib+ liposomal doxorubicin vs bortezomib) 23 confirm the clinical benefit of combination therapy, however, the role of sequence of administration is unclear with some data suggesting that the DNA damaging agent should be given prior to bortezomib to maximize the synergistic effect 21, 24 . Based on preclinical and clinical data, we designed a randomized phase I study combining escalating doses of bortezomib with standard HD melphalan with the intent of asking two major questions: First, what is the maximum tolerated dose (MTD) of bortezomib that can be safely administered with HD melphalan? Second, does the sequence of administration impact the efficacy or toxicity of the combination? We choose to give a single dose of bortezomib in order to address the synergy interaction between bortezomib and melphalan rather than a multiple dose approach where one could argue that the benefit for the combination was related to independent efficacy of the 2 agents. Our study indicates that the addition of bortezomib to HD melphalan is safe and that the biologically optimal sequence is to deliver the proteasome inhibitor following exposure to melphalan.
Patients and Methods:
Eligibility Criteria
Eligible subjects for this trial were selected from the population of MM patients referred to the following induction therapy. Induction therapy for the trial was not specified, and there was no limit on the number of prior lines before HDT and autologous transplant. Suitable patients had to meet eligibility criteria for HDT based on standard institutional guidelines for autologous transplant including performance status, organ function and co-morbidities 25 . All patients signed an informed consent for participation in an IRB approved investigational protocol (NCI #NCT00793650).
Stem cell collection and conditioning regimen
Peripheral blood hematopoietic progenitor cell grafts were collected by apheresis following chemo-mobilization in conjunction with 10-15 ug/kg/day hematopoietic growth factors (G-CSF or G-CSF + GM-CSF), or cytokines alone. The method of collection (chemomobilization or growth factors) was not specified in the protocol. were not part utilized nor planned for this study based upon our hypothesis that DNA repair inhibition could be achieved without escalation beyond1.6mg/m 2 . Dose escalation for each arm was performed using the Escalation With Overdose Control methodology described below.
Individual patients only received one dose of bortezomib.
Transplant patients were housed in private rooms outfitted with HEPA filtered air during their hospital stay, and they received standard antibacterial, antiviral, and antifungal prophylaxis 25 . Blood products were administered according to standard transfusion parameters
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Statistics
Patients were randomly allocated to receive bortezomib before melphalan (Arm A) or bortezomib after melphalan (Arm B). Dose escalation started at 1.0mg/m 2 in both arms, and escalated independently based upon observed toxicities for each arm. For each arm, the MTD was defined to be the dose level at which the probability of grade 3 non-hematological toxicity or grade 4 hematological toxicity (θ) resulted was equal to 0.33. Dose escalation for both arms was carried out using the Escalation With Overdose Control (EWOC) algorithm 26,27 28 . The dose for each subsequent patient was determined so that, on the basis of all available data, the posterior probability that this dose exceeded the MTD was equal to a pre-specified value α, where α = 0. In each arm, prior distributions for the MTD and the probability of DLT at the initial dose were taken, and uniformly distributed over their respective intervals.
Calculation of response was based on greatest disease burden prior to transplant. Overall survival (OS) and PFS curves were estimated using the nonparametric Kaplan-Meier estimator.
Comparison of OS and PFS was carried out using the Log-rank test. The two-sample t-test was used to compare the mean annexin V and PI staining between the two arms after applying a log transformation to the data.
Results:
Demographics Thirty-nine patients were enrolled into this trial, 19 randomized to Arm A, and 20 
Response
The overall response rate for the trial was 87% (PR or better) as assessed at day +100 post transplant. Among patients treated on Arm A, 47% achieved >VGPR with 11% achieving a CR. . Among patients treated on Arm B, 55% achieved >VGPR with 30% achieving a CR ( There were no differences in PFS and OS between the two arms (p=0.48 and p=0.60, respectively). When responses were evaluated among the fraction of patients that had received prior bortezomib, there was no diminution in the overall fraction of patients that achieved >VGPR, with Arm B containing a greater number of CRs than was seen in Arm A.
Correlative Studies
Discussion
The use of high dose therapy and autologous transplant was the first major advance in the therapy of patients with newly diagnosed myeloma, and is able to improve the median progression free and overall survival, yet HDT does not offer benefit for all patients. The
Research. proteasome inhibitor bortezomib has demonstrated activity in myeloma patients, and has proven to have synergistic activity when combined with alkylators and anthracyclines 22, 23 . Based upon this observation, we designed the current trial to test the safety, efficacy, and optimal sequence for combining a single dose of bortezomib with high dose melphalan and autologous transplant.
This trial, via its unique design and correlative studies, provides 4 major features which separate it from other HDT trials performed in multiple myeloma to date: (1) the novel dose escalation scheme, (2) the patient population studied, (3) the addition of a novel agent to a standard conditioning regimen, and (4) the evaluation of drug sequencing using correlative measures of myeloma apoptosis.
The escalation with overdose control (EWOC) statistical method is one that utilizes individual patient experiences, allows more rapid dose escalation, while minimizing the number of patients that are under-dosed in a phase I trial 29 . The basic premise behind this Bayesian method for dose escalation is that each patient provides real time assessment of toxicity and allows for dose escalation if no DLT is encountered and dose de-escalation if the patient exhibits DLT. The operating characteristics of this design were studied using extensive simulations, 26 and it was demonstrated that, relative to the continuous reassessment method (CRM), EWOC overdosed a smaller proportion of patients and estimated the maximum tolerated dose with comparable accuracy. When compared to different up-and-down schemes, including "3+3" designs, EWOC assigned fewer patients to either sub-therapeutic or toxic dose levels, treated more patients at optimal dose levels and estimated the MTD with smaller average bias and mean squared error.
The patients enrolled in this trial were a relatively resistant cohort, who had not achieved
>VGPR following at least 1 induction regimen, and had plasma cells detectable in their marrow
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on 1-3) . The overall response rate as measured by >VGPR at day +100 post transplant is 51% for all patients, and in Arm B the >VGPR rate was 55%. The overall response rate and >VGPR rate was independent of prior bortezomib exposure. However, because many of these patients did not receive their initial induction nor diagnostic marrow at our center, more recent risk stratification using β2M and cytogenetics was not available on a large number of patients, and thus differences in response between the groups could be confounded by unbalanced prognostic group differences.
In a contemporary retrospective review reported by Kumar et al from the Mayo clinic, MM patients similar to those enrolled on this trial with measurable disease at the time of transplant (m protein of >1gm/dl or urine proteins of >200mg/day) achieved >VGPR rate of 30% 30 . This suggests that the inclusion of a single dose of bortezomib in our trial enhances the VGPR rate for a group of patients in whom we know that responses are suboptimal. In a trial with a similar concept of adding bortezomib to high dose melphalan from the IFM, a similarly high overall and >VGPR rate (70%) was observed, though 30% of patients in the IFM trial had already achieved >VGPR prior to high dose therapy. Thus, though the IFM study is further corroborative evidence that the overall response rate following HDT can be improved with the addition of bortezomib, the patient population (superior induction response in IFM), dosing schema of bortezomib (2 doses before and 2 after HD melphalan), and absence of correlative . Additionally, the fact that prior bortezomib exposure did not impact the overall response rate nor the fraction of patients who achieved a VGPR suggests that the combination is greater than simply the 2 individual agents acting independently, but confirmation that the preclinical hypothesis supporting the combination is at work, and results in clinical benefit.
Furthermore, by delivering a single dose of bortezomib, we were able to test the clinical synergy of the combination, and in fact demonstrated comparable clinical efficacy to other trials that used multiple doses of bortezomib with HD melphalan 31 .
Other investigators have attempted to enhance the response rate and efficacy of HDT by adding bortezomib to the conditioning. The Arkansas group has reported that delivering hyperfractionated melphalan with escalating doses of bortezomib was safe, and effective in a small cohort of patients 32 . The MDACC group has also presented preliminary data on a combination of melphalan, arsenic trioxide (ATO), ascorbic acid (AA) and bortezomib in a phase II trial, but demonstrated no benefit for the addition of bortezomib 33 . However, the concomitant administration of ascorbic acid may have compromised the efficacy of the combination, as our group and others have reported that ascorbic acid can inhibit the effects of bortezomib [34] [35] [36] .
Finally, our comparison of apoptosis in CD138+ cells across treatment arms was designed to be a method by which we could functionally determine the biologically optimal sequence of administration for bortezomib. Despite our small sample, there was a significant difference between the fraction of PI positive malignant plasma cells in the marrow on day 0 favoring the sequence of bortezomib following melphalan (Arm B), and this corresponds to a trend towards a higher CR rate among patients treated in that arm as well (6/20 for Arm B vs 2/19 for Arm A). Interestingly, among all tested patients, we were clearly able to assess the However, due to the small sample size and intrinsic difficulties in collecting tumor samples on all patients, we cannot definitively confirm that our correlative studies confirm sequence specificity.
In conclusion, the efficacy of adding bortezomib to conventional chemotherapy is one that has been tested and confirmed in the context of standard dose therapy 22, 23, 37 , but is not one that has been fully evaluated with HD melphalan and autologous transplant. Based upon laboratory rationale for the use of proteasome inhibitors in conjunction with melphalan, this combination represents a novel way to improve efficacy, yet maintains a similar toxicity profile to high dose melphalan alone, which has not been easily accomplished by adding radiation, additional chemotherapy agents, or radio-immunotherapy to the conditioning regimen for myeloma transplants. Our pilot trial supports the idea that bortezomib can be safely added to high dose melphalan, that the fraction of apoptotic plasma cells in the marrow is increased when bortezomib is given following melphalan, and that the VGPR or better rate is superior to that seen for a similar group of patients with poor responses to induction therapy from historical data.
While this trial appears promising, the true efficacy of this combination needs to be further 
